DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z5t88w/lung_cancer_drug) has announced the addition of the "Lung Cancer Drug Pipeline Update 2014" report to their offering.
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers.
High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today 364 companies plus partners developing 495 lung cancer drugs in 581 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 222 drugs.
Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 325 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 313 out of the 316 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 68 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed # 39
- Pre-registration # 5
- Phase III # 42
- Phase II # 219
- Phase I # 135
- Preclinical # 94
- No Data # 2
- Suspended # 11
Ceased # 222
For more information visit http://www.researchandmarkets.com/research/z5t88w/lung_cancer_drug